Agenus – The Right Combination
Agenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes.
Enter #ctad2019 – Biogen
sample size 3285 patients at 348 sites in 20 countries Population Early Alzheimer’s disease (MCI due to Alzheimer’s disease + mild Alzheimer’s disease dementia) • MMSE 24-30, CDR-G 0.5, RBANS ≤ 85, with confirmed amyloid pathology Doses Two dosing regimens (low and high) and placebo; randomized 1:1:1 Primary endpoint CDR-SB at 18 months
Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders.
Anavex Life Sciences
Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson’s Disease and Alzheimer’s Disease)
Best Contract Development and Manufacturing – Adare Pharma …
Adare Pharma Solutions is a global technology-driven CDMO providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health, and OTC markets.
Michela Gallagher – Wikipedia
Michela Gallagher is an American cognitive psychologist and neuroscientist.She is the Krieger-Eisenhower Professor of Psychology and Neuroscience at Johns Hopkins University.Her scientific work has changed the model of neurocognitive aging, and developed new indices for its study.
AgeneBio – Funding, Financials, Valuation & Investors
AgeneBio is funded by 4 investors. National Institutes of Health and Alzheimer’s Drug Discovery Foundation are the most recent investors. AgeneBio has a post-money valuation in the range of $10M to $50M as of Oct 17, 2014, according to PrivCo. Sign up for a free trial to view exact valuation and search companies with similar valuations.
Cerecor, Inc. (CERC)
CERC-002. CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes (part of the Tumor Necrosis Super Family 14)), fully human, monoclonal antibody being developed as a treatment for COVID-19 associated ARDS and Pediatric Crohn’s Disease.
Adesis – Custom Molecular Synthesis, Research …
Adesis takes pride in supporting pharmaceutical and biotech industry clients – helping them solve the world’s most pressing medicinal chemistry, process scale-up and manufacturing challenges. Find out more about how we expand pharmaceutical R&D teams, reducing costs and speeding time to market.
Emergent BioSolutions – Purpose. People. Performance.
Notice to Emergent BioSolutions candidates. Please note: if you are logged into your account/profile, in order to sign out you must return to your main profile page by clicking on View Account, where the “Sign Out” link is displayed. This site is not supported by Internet Explorer 9 and 10.